China · Delayed Price · Currency is CNY Kexing Biopharm Statistics
Total Valuation
Kexing Biopharm has a market cap or net worth of CNY 4.19 billion. The enterprise value is 5.04 billion.
| Market Cap | 4.19B |
| Enterprise Value | 5.04B |
Important Dates
The last earnings date was Saturday, August 22, 2026.
| Earnings Date | Aug 22, 2026 |
| Ex-Dividend Date | Jun 15, 2026 |
Share Statistics
Kexing Biopharm has 197.86 million shares outstanding. The number of shares has increased by 0.03% in one year.
| Current Share Class | 197.86M |
| Shares Outstanding | 197.86M |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | -2.33% |
| Owned by Insiders (%) | 51.69% |
| Owned by Institutions (%) | 12.82% |
| Float | 95.59M |
Valuation Ratios
The trailing PE ratio is 20.01 and the forward PE ratio is 34.15.
| PE Ratio | 20.01 |
| Forward PE | 34.15 |
| PS Ratio | 2.91 |
| PB Ratio | 2.28 |
| P/TBV Ratio | 2.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 51.41 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 24.09 |
| EV / Sales | 3.50 |
| EV / EBITDA | 73.56 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.34, with a Debt / Equity ratio of 0.79.
| Current Ratio | 1.34 |
| Quick Ratio | 1.14 |
| Debt / Equity | 0.79 |
| Debt / EBITDA | 21.30 |
| Debt / FCF | -163.86 |
| Interest Coverage | -1.67 |
Financial Efficiency
Return on equity (ROE) is 11.71% and return on invested capital (ROIC) is -1.28%.
| Return on Equity (ROE) | 11.71% |
| Return on Assets (ROA) | -0.66% |
| Return on Invested Capital (ROIC) | -1.28% |
| Return on Capital Employed (ROCE) | -1.42% |
| Weighted Average Cost of Capital (WACC) | 5.03% |
| Revenue Per Employee | 1.37M |
| Profits Per Employee | 199,586 |
| Employee Count | 1,048 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 4.43 |
Taxes
In the past 12 months, Kexing Biopharm has paid 22.37 million in taxes.
| Income Tax | 22.37M |
| Effective Tax Rate | 9.79% |
Stock Price Statistics
The stock price has decreased by -52.23% in the last 52 weeks. The beta is 0.37, so Kexing Biopharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | -52.23% |
| 50-Day Moving Average | 20.19 |
| 200-Day Moving Average | 27.17 |
| Relative Strength Index (RSI) | 51.97 |
| Average Volume (20 Days) | 9,483,183 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kexing Biopharm had revenue of CNY 1.44 billion and earned 209.17 million in profits. Earnings per share was 1.06.
| Revenue | 1.44B |
| Gross Profit | 853.91M |
| Operating Income | -36.87M |
| Pretax Income | 228.63M |
| Net Income | 209.17M |
| EBITDA | 62.71M |
| EBIT | -36.87M |
| Earnings Per Share (EPS) | 1.06 |
Balance Sheet
The company has 609.87 million in cash and 1.46 billion in debt, with a net cash position of -849.34 million or -4.29 per share.
| Cash & Cash Equivalents | 609.87M |
| Total Debt | 1.46B |
| Net Cash | -849.34M |
| Net Cash Per Share | -4.29 |
| Equity (Book Value) | 1.84B |
| Book Value Per Share | 9.44 |
| Working Capital | 386.25M |
Cash Flow
In the last 12 months, operating cash flow was 81.48 million and capital expenditures -90.38 million, giving a free cash flow of -8.91 million.
| Operating Cash Flow | 81.48M |
| Capital Expenditures | -90.38M |
| Depreciation & Amortization | 99.57M |
| Net Borrowing | 74.90M |
| Free Cash Flow | -8.91M |
| FCF Per Share | -0.05 |
Margins
Gross margin is 59.27%, with operating and profit margins of -2.56% and 14.52%.
| Gross Margin | 59.27% |
| Operating Margin | -2.56% |
| Pretax Margin | 15.87% |
| Profit Margin | 14.52% |
| EBITDA Margin | 4.35% |
| EBIT Margin | -2.56% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.25, which amounts to a dividend yield of 1.22%.
| Dividend Per Share | 0.25 |
| Dividend Yield | 1.22% |
| Dividend Growth (YoY) | 212.50% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 43.79% |
| Buyback Yield | -0.03% |
| Shareholder Yield | 1.19% |
| Earnings Yield | 4.99% |
| FCF Yield | -0.21% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |